ClinicalTrials.gg
RecruitingNCT04443595Updated Jun 23, 2020

Dual-scopic Pancreatic Necrosectomy (DPN)

An interventional study of Dual-scopic pancreatic necrosectomy(DPN) in Pancreatitis, Pancreatitis, Acute Necrotizing and Pancreatic Diseases, sponsored by First People's Hospital of Hangzhou. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-06-23.

Primary conditionPancreatitis, Acute NecrotizingRegistry: PancreatitisReclassifiedWhy we changed it
Registry
Pancreatitis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Pancreatitis, Acute Necrotizing
Why
  1. The study's listed conditions name Pancreatitis, Acute Necrotizing, a narrower term within Pancreatitis.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by First People's Hospital of Hangzhou · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Pancreatitis, Acute Necrotizing with a site in China — 6 open to participants now, 6 under way, none of them phase 3. Pancreatitis, Acute Necrotizing · China.

Planned enrollment
14th of 14
20 · median 135
Started
2020
with 1 other
No phase
8 of 17
4 open now
Registered
11th of 17
by date
Lead sponsor
2 of 17
First People's Hospital of Hangzhou

Among the 17 studies in Pancreatitis, Acute Necrotizing with a site in China, this one is the 14th largest by planned enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2020, is one of 8 with no phase, and was the 11th registered.

Pancreatitis, Acute Necrotizing

75 studies on the registry are indexed under Pancreatitis, Acute Necrotizing; 20 are open to participants now.

Browse Pancreatitis, Acute Necrotizing studies →

Open to participants now

6 of the 17 studies in Pancreatitis, Acute Necrotizing with a site in China are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 12 Pancreatitis, Acute Necrotizing studies recruiting now, 9 (75%) set no upper age limit and 3 (25%) stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Pancreatitis, Acute Necrotizing with a site in China, or all of them as a file.
02

Study summary

The LPN procedure is performed under general anesthesia. The transperitoneal access to peripancreatic space is via the gastro-colic ligament and greater omentum, effusion and pus is removed by laparoscopic forceps and suction. Laparoscopic cholecystectomy (LC) is performed during the LPN procedure on patients with indication.

The NPN procedure is followed by the standard retroperitoneal approach. After the catheter is exchanged over a guide wire and serially dilated up from 6F to 24F followed by Seldinger technique, the access track to the necrotic cavity is established. A nephroscope is inserted into the cavity through the track for debridement. Using forceps and suction, the peripancreatic solid necrotic tissue and pus is grasped and removed. A large-bore irrigating drain is left in the cavity, with continuous irrigation by warm normal saline solution at a rate of 100-125 ml/h after surgery.

03

Conditions studied

  • Pancreatitis
  • Pancreatitis, Acute Necrotizing
  • Pancreatic Diseases

Browse trials for

04

In context

Pancreatitis, Acute Necrotizing Reclassified

75 studies on the registry are indexed under Pancreatitis, Acute Necrotizing; 20 are open to participants now.

This study's planned enrollment of 20 is below the median of 70 across 47 interventional studies indexed under Pancreatitis, Acute Necrotizing.

Browse Pancreatitis, Acute Necrotizing studies →

Lead sponsor

First People's Hospital of Hangzhou is the lead sponsor of 73 studies on the registry; 28 are open to participants now.

Compared within Pancreatitis, Acute Necrotizing, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Pancreatitis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All patients ages 18 or above admitted to UPMC with a diagnosis of AP based on at least 2 of the following criteria:(i) abdominal pain characteristic of AP (ii) serum amylase and/or lipase ≥ 3 times the (iii) characteristic findings of AP on abdominal CT scan will be screened for study enrollment.

Exclusion criteria

Exclusion Criteria:

  • Less than 18 years of age
  • Pregnant women
  • Presence of renal dysfunction (Cr>1.5mg/dL)
  • Pre existing heart dysfunction or classification score above III
  • Coagulation disorder
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Experimental

    Treatment of Acute Severe Pancreatitis with DPN

    Procedure: Dual-scopic pancreatic necrosectomy(DPN)

Interventions

  • ProcedureDual-scopic pancreatic necrosectomy(DPN)

    Treatment of Acute Severe Pancreatitis with DPN

07

What researchers measure

Primary outcomes

  1. Complication Rate

    Proportion of patients with perioperative complications

    Time frame: through study completion, an average of 24 weeks

  2. Mortality

    Proportion of patients dying in the perioperative period

    Time frame: through study completion, an average of 24 weeks

Secondary outcomes

  1. Hospital stay

    Length of hospital stay

    Time frame: through study completion, an average of 24 weeks

08

Study locations

1 of 1 sites recruiting
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2020; primary completion for Dec 2025, 65 months later.

Of 20 interventional studies with no phase under Pancreatitis, Acute Necrotizing, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 36. This study's planned 65 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2020
First posted
Jun 23, 2020
StartEst.
Jul 1, 2020
Primary completionEst.
Dec 31, 2025
CompletionEst.
Dec 31, 2025
Last update
Jun 23, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04443595
Lead sponsor
First People's Hospital of Hangzhou
Responsible party
Yang Cai (Director, Deputy Chief of Hepatobiliary and Pancreatic Surgery, Professor., First People's Hospital of Hangzhou) — Principal investigator
First posted
Jun 23, 2020
Start date
Jul 1, 2020 (estimated)
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Jun 23, 2020

Study contacts

Yang Cai
Contact
caiyang6969@163.com
+8613867136969

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion